<code id='193F9DC34D'></code><style id='193F9DC34D'></style>
    • <acronym id='193F9DC34D'></acronym>
      <center id='193F9DC34D'><center id='193F9DC34D'><tfoot id='193F9DC34D'></tfoot></center><abbr id='193F9DC34D'><dir id='193F9DC34D'><tfoot id='193F9DC34D'></tfoot><noframes id='193F9DC34D'>

    • <optgroup id='193F9DC34D'><strike id='193F9DC34D'><sup id='193F9DC34D'></sup></strike><code id='193F9DC34D'></code></optgroup>
        1. <b id='193F9DC34D'><label id='193F9DC34D'><select id='193F9DC34D'><dt id='193F9DC34D'><span id='193F9DC34D'></span></dt></select></label></b><u id='193F9DC34D'></u>
          <i id='193F9DC34D'><strike id='193F9DC34D'><tt id='193F9DC34D'><pre id='193F9DC34D'></pre></tt></strike></i>

          leisure time

          leisure time

          author:focus    Page View:51175
          Doctor Monica Bertagnolli, a white woman with short hair and bangs, sits at a hearing behind her name tag — coverage from STAT
          National Institutes of Health Director Monica Bertagnolli testifies during her Senate HELP Committee confirmation hearing on Oct. 18 in Washington. Kevin Dietsch/Getty Images

          WASHINGTON — The new National Institutes of Health director, Monica Bertagnolli, said it’s a “failure” that enrollment in government-funded clinical trials has lagged behind those funded by the pharmaceutical industry.

          “If you just look at the number of patients who go on government-funded trials, it’s been completely flat over the last decade,” she said at a meeting of the advocacy group Friends of Cancer Research. “If you go and look at the number of people who go on pharma-sponsored trials, it’s just this commitment and this increase.”

          advertisement

          A Johns Hopkins University study published in 2015 showed that the pharmaceutical industry funds six times more clinical trials than the government. Industry-sponsored trials increased 43% from 2006 to 2014, while newly registered NIH-funded trials decreased 24% over the same period.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          explore

          FDA approval of Sarepta Duchenne genetic therapy gives me hope
          FDA approval of Sarepta Duchenne genetic therapy gives me hope

          Duchennemusculardystrophyhistopathology.Dr.EdwinP.Ewing,Jr./CDCWhenIwasdiagnosedwithDuchennemuscular

          read more
          How the BIOSECURE Act is already affecting U.S., Chinese life science firms
          How the BIOSECURE Act is already affecting U.S., Chinese life science firms

          ARIANADREHSLER/AFPviaGettyImagesSANDIEGO— U.S.legislationthatseekstorestrictAmericanbiotechsfromwork

          read more
          Drug repurposing or repositioning? The language matters
          Drug repurposing or repositioning? The language matters

          AdobeFindinganewmedicineisnevereasy.Butdevelopingtreatmentsforpatientswithrarediseases—conditionstha

          read more

          Study: Why relieving medical debt did not improve financial outcomes

          AdobePhilanthropistsandfoundationsliketheoneIworkfortakealotofcalculatedrisks.Weinvestinresearch,adv